Create a free account to unlock these features!
Track
 
11 users tracking
NYSE: ABT   53.46 -0.31 (-0.58%)  Friday4:01 PM ET
 
                   
Name: Abbott Laboratories
Industries: Biotech
Revenue: $30.76B ¹
Profit: $5.75B ¹
Employees: 69,000
Headquarters: 100 ABBOTT PARK ROAD
D-322 AP6D
ABBOTT PARK, Illinois 60064-3500
United States Of America
Website:
¹ TTM figures for 31-Dec-2009
Abbott Labs tries to Ensure good health. Abbott Laboratories (NYSE: ABT) is based in Abbott Park, IL. The company deals with a broad and diversified line of healthcare products. Its primary business segments are Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products, which produce a broad line of adult and pediatric pharmaceuticals and nutritional products; diagnostic systems and tests; surgical devices; acute care injectable drugs; and others. Founded in 1888,
Abbott Labs tries to Ensure good health. Abbott Laboratories (NYSE: ABT) is based in Abbott Park, IL. The company deals with a broad and diversified line of healthcare products. Its primary business segments are Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products, which produce a broad line of adult and pediatric pharmaceuticals and nutritional products; diagnostic systems and tests; surgical devices; acute care injectable drugs; and others. Founded in 1888, the company had 2008 revenue of about $29.5 billion and has about 69,000 employees. In February 2009, it completed its acquisition of Advanced Medical Optics which is now a wholly owned subsidiary of Abbott and has been renamed Abbott Medical Optics Inc.
... more
All News - 1000's of sources
loading news
 new tracked items.
Tracker changed. Refresh? yes | no
Sources
 
 
check at least one:
 
 
 
  
1269609 1 hour:
Meridian Biosciences and Other Profitable Market Lessons
One of the biggest challenges to buying and holding a stock for the long term is the wait through thick and thin for the expectations of a particular stock to materialize. In a process of elimination, the New Low Observer team has narrowed down the steps to determining quality stocks by relegating it ... - read more at Seeking Alpha
1268980 21 hours:
bullish dividends
"If 'buy & hold' is dead, then I am the embalming fluid" So is buy & hold still dead? Lil' Wayne and I never thought so. The S&P 500 is up 53% over the past year... Dividends are being raised all over the place by firms like Coke (KO), Wal-Mart (WMT), Pepsico (PEP), Rogers (RCI.B), Abbott ... - read more at Benzinga
1268338 3/19/10:
Jim Cramer's Lightning Round Picks (APD, WEN, MCD, TSRA, VSI, ...
CNBC Mad Money's Jim Cramer said in the segment of his show called Lightning Round that he likes Air Products & Chemicals, Inc.Chemicals, Inc. (NYSE: APD), but the stock has moved up too much and should be sold. Air Products & Chemicals (APD)Chemicals (APD) dropped 0.43% today. Cramer likes Wendy's Arby's Group Inc. (NYSE: ... - read more at Benzinga
1266399 3/19/10:
Zocor Can Increase Chance Of Muscle Injury & Kidney Damage: ...
While myopathy (muscle injury) is a known side effect for all cholesterol-lowering statin medications, the FDA has just issued a warning that, when prescribed and used at higher doses, Zocor (generic name: simvastatin) carries with it a greater risk of developing muscle injury, including the most serious ... - read more at Consumerist
1266148 3/19/10:
BREAKING NEWS: FDA issues muscle injury alert for Zocor
The FDA today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg. The agency based its warning on clinical trials, observational studies, adverse event reports, and prescription use data. ... - read more at Fierce HealthCare
1265257 3/19/10:
FDA warns Zocor, Vytorin raise muscle injury risk
BOSTON (MarketWatch) -- The U.S. Food and Drug Administration warned Friday that high doses of the popular cholesterol-controlling drugs Zocor and Vytorin could increase the risk of developing rhabdomyolysis, an extremely serious muscle injury that can sometimes lead to death . Both Zocor and Vytorin ... - read more at Market Watch
1265178 3/19/10:
Abbott Labs (ABT) Dividend Stock Analysis
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company is a component of the S&P 500 and the dividend ... - read more at iStockAnalyst
1263481 3/19/10:
Seth Klarman's Baupost Group Wins Big With Facet Biotech
Seth Klarman's hedge fund Baupost Group recently filed an amended 13D and a Form 4 with the SEC in regards to shares of Facet Biotech (FACT). In the Form 4, we see that Klarman has sold 1,506,875 shares at a price of $27 per share. This transaction took place on March 16th, 2010 and Baupost Group is ... - read more at SeekingAlpha.com
tags: Biogen Idec 
1263267 3/19/10:
Abbott Labs (ABT) Dividend Stock Analysis
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company is a component of the S&P 500 and the dividend ... - read more at Dobromir Stoyanov
1259163 3/18/10:
Study: Mini Clip Safer Than Heart-Valve Surgery
ATLANTA - Many Americans with leaky heart valves soon might be able to get them fixed without open-heart surgery. A study showed that a tiny clip implanted through an artery was safer and nearly as effective as surgery, doctors reported Sunday. The device is already on sale in Europe, and its ... - read more at Huffington Post
NYSE: ABT - FridayMar 194:01 PM ET
53.46 -0.31  (-0.58%)
Vol: 16.33M
High: 53.90
Low: 53.19
Mkt Cap: 83.00B
52Wk High: 56.79
52Wk Low: 41.27
P/E: 14.53
Div: 1.76
Yield: 3.29
1d | 1m | 3m | 6m | 1y | 5y | 10y
loading
previous day close
Financial Performance
Income (in thousands of USD) 3 months ending
2009-12-31
12 months ending
2009-12-31
Revenue 8,790,127 30,764,707
Net Income 4,169,191 5,745,838
Balance Sheet (in thousands of USD)
Current Assets 23,313,891 23,313,891
Total Assets 52,416,623 52,416,623
Current Liabilities 13,049,489 13,049,489
Total Liabilities 29,560,996 29,560,996
Total Shareholders Equity 22,855,627 22,855,627
Cash Flow (in thousands of USD)
Cash from Operating Activity 1,832,617 7,275,160
Cash from Investing Activity 1,562,877 -3,698,710
Cash from Financing Activity 503,373 1,002,019
Change in Cash 3,933,424 4,697,317
Key Stats 3 months ending
2009-12-31
Trailing 12 Months
Gross Profit Margin 56.95% 57.06%
Net Profit Margin 47.43% 18.68%
Return on Assets 7.95% 10.96%
Return on Equity 18.24% 25.14%
Return on Invested Capital 4.42% 13.39%
© 2010 Tracked.com. All Rights Reserved.   About Us   |  Tour   |  Jobs   |  Contact Us   |  Terms of Use   |  Privacy Policy   |  Tracked.com Insights